Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01869829 · ClinicalTrials.gov registry record
PEACE: Pediatric Antifungal Comparative Effectiveness
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 750
- Enrollment target
NCT01869829: Completed study, sponsored by Duke University.
NCT01869829 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 750 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01869829 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 750 participants
- Enrollment target
Study Summary
The overarching objective is to develop new evidence-based treatment guidelines for invasive fungal diseases in children. To accomplish that, this protocol will focus on two specific aims: 1) Compare the effectiveness of echinocandin versus amphotericin B or triazole antifungal therapy for pediatric invasive candidiasis and for the subset of patients with invasive candidemia; 2) Characterize the incidence rate of inpatient pediatric invasive candidiasis per hospital admissions.
Interventions
- DRUG Observational antifungal therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2015-01 |
| Est. Completion | 2018-04 |
What the finished NCT01869829 record still lists
NCT01869829 is an observational study that tracks outcomes without assigning an intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Observational antifungal therapy is the first listed.
NCT01869829 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01869829 about?
NCT01869829 is a clinical study titled "PEACE: Pediatric Antifungal Comparative Effectiveness". The overarching objective is to develop new evidence-based treatment guidelines for invasive fungal diseases in children. To accomplish that, this protocol will focus on two specific aims: 1) Compare the effectiveness of echinocandin versus amphotericin B or triazole antifungal therapy for pediatric...
What is the current status of trial NCT01869829?
This trial is currently completed. The enrollment target is 750 participants. The study started on 2015-01. Estimated completion is 2018-04.
What interventions are being tested in trial NCT01869829?
The interventions under investigation include: Observational antifungal therapy (DRUG).
Who is sponsoring clinical trial NCT01869829?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia